Ameriprise
MRSN

Ameriprise’s Mersana Therapeutics MRSN Stock Holding History

Ameriprise’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,133
Closed -$76.3K – 4107
2024
Q4 		$76.3K Buy
2,133
+307
+17% +$15.9K ﹤0.01% 3979
2024
Q3 		$86.3K Buy
1,826
+4
+0.2% +$176 ﹤0.01% 3847
2024
Q2 		$91.5K Buy
1,822
+1,106
+154% +$80K ﹤0.01% 3782
2024
Q1 		$80.2K Sell
716
-924
-56% -$91.9K ﹤0.01% 3793
2023
Q4 		$95.1K Buy
+1,640
New +$66K ﹤0.01% 3820
2023
Q3 		– Sell
-22,891
Closed -$1.88M – 3936
2023
Q2 		$1.88M Buy
+22,891
New +$3.35M ﹤0.01% 2901
2023
Q1 		– Sell
-1,082
Closed -$158K – 4007
2022
Q4 		$158K Sell
1,082
-13
-1% -$2.2K ﹤0.01% 3746
2022
Q3 		$185K Buy
+1,095
New +$178K ﹤0.01% 3725
2021
Q1 		– Sell
-337
Closed -$225K – 3877
2020
Q4 		$225K Buy
+337
New +$187K ﹤0.01% 3596
2019
Q4 		– Sell
-779
Closed -$31K – 3743
2019
Q3 		$31K Sell
779
-816
-51% -$59.3K ﹤0.01% 3679
2019
Q2 		$161K Buy
+1,595
New +$188K ﹤0.01% 3613

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ameriprise's MRSN Position: Q1 2025 in Review

Ameriprise sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 2,133 shares — an estimated $76.3K sold.

Ameriprise first reported a position in MRSN in Q2 2019 and held it in 11 quarters. The position peaked at $1.88M in Q2 2023. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Ameriprise reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ameriprise sold 2,133 Mersana Therapeutics shares in Q1 2025, an estimated $76.3K.
  • Ameriprise first reported a position in Mersana Therapeutics in Q2 2019 and held it in 11 quarters.
  • Ameriprise's Mersana Therapeutics position peaked at $1.88M in Q2 2023.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Ameriprise's 13F filing for Q1 2025, filed 14 May 2025.